RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $524
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Conor McNamara maintains an Outperform rating on Bio-Rad Laboratories (NYSE:BIO) and raises the price target from $522 to $524.
August 04, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Bio-Rad Laboratories and raises the price target from $522 to $524. This could potentially lead to an increase in the stock's price.
The Outperform rating maintained by RBC Capital indicates that they expect Bio-Rad Laboratories to outperform the general market. The increase in the price target from $522 to $524 suggests that they believe the stock is undervalued at its current price, which could lead to an increase in the stock's price as the market adjusts to this new information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100